Congenital diaphragmatic hernia

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

Retrieved on: 
Wednesday, April 3, 2024
ART, OXY, Annual report, Unitary state, Risk, Patient, Coma, Abdomen, Research, Meconium, Meconium aspiration syndrome, Human, Congenital diaphragmatic hernia, Intubation, Pharmaceutical industry

Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.

Key Points: 
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.
  • Inspira aims to explore how this potential additional application of the INSPIRA ART100 device to provide neonates with vital respiratory support could replace the currently used mechanical ventilators.
  • "Inspira is dedicated to pushing the boundaries of medical technology to save and improve lives," remarked Dagi Ben-Noon, CEO of Inspira Technologies.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Orphan designation: rhizobium rhizogenes,lipopolysaccharide Treatment of congenital diaphragmatic hernia, 25/07/2023 Positive

Retrieved on: 
Sunday, February 4, 2024
COMP, IRIS, European Commission, Rhizobium, Congenital diaphragmatic hernia, Committee, Patient, Business, EMA, Pharmaceutical industry

Key facts

Key Points: 
  • Key facts
    - Active substance
    - rhizobium rhizogenes
    - lipopolysaccharide
    - Intended use
    - Treatment of congenital diaphragmatic hernia
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2801
    - Date of designation
    - Sponsor
    Crazy Science & Business S.L.
  • Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Children's Hospital of Philadelphia Celebrates 27th Annual Fetal Surgery Family Reunion at the Philadelphia Zoo

Retrieved on: 
Monday, June 5, 2023
Test management, CHOP, Morbilliform, Congenital diaphragmatic hernia, Spina bifida, Philadelphia, Mother, Surgeon, MD, Patient, Birth defect, Hospital, Birth, CFDT, Philadelphia Zoo, Children's Hospital of Philadelphia, Birth control

PHILADELPHIA, June 5, 2023 /PRNewswire/ -- Yesterday, more than 3,000 people gathered at the Philadelphia Zoo to celebrate the 27th Children's Hospital of Philadelphia (CHOP) Fetal Family Reunion, representing patients and families from across the country.

Key Points: 
  • PHILADELPHIA, June 5, 2023 /PRNewswire/ -- Yesterday, more than 3,000 people gathered at the Philadelphia Zoo to celebrate the 27th Children's Hospital of Philadelphia (CHOP) Fetal Family Reunion, representing patients and families from across the country.
  • The reunion brings together a unique community of families who have shared similar experiences.
  • Babies diagnosed before birth either underwent fetal surgery to treat the condition in utero or received highly complex care immediately after birth.
  • The team has also managed thousands of pregnancies complicated by birth defects in which newborns need immediate specialized medical care or surgery after delivery.

Children's Hospital of Philadelphia Celebrates 5,000 Deliveries in Garbose Family Special Delivery Unit

Retrieved on: 
Wednesday, November 30, 2022
Growth, Fetus, Children's Hospital of Philadelphia, Diagnosis, SCT, Electrical telegraph, Gastroschisis, Ventricular septal defect, Hospital, Mother, Garbose Building, Non-functional testing, Health, Physician, CGC, Neoplasm, Omphalocele, Spina bifida, Birth, Parent, Prussia, Congenital diaphragmatic hernia, Harriet, Hydrops, CFDT, Birth defect, Research, Delivery unit, SDU, CHOP, Woman, Surgeon, Sacrococcygeal teratoma, Dentistry, Toy, Medical imaging, MD, Child, Lyra, Treatment

PHILADELPHIA, Nov. 30, 2022 /PRNewswire/ -- More than 14 years after opening the Garbose Family Special Delivery Unit (SDU), the world's first birth facility exclusively for mothers carrying babies with known birth defects, Children's Hospital of Philadelphia (CHOP) is celebrating its 5,000th delivery.

Key Points: 
  • PHILADELPHIA, Nov. 30, 2022 /PRNewswire/ -- More than 14 years after opening the Garbose Family Special Delivery Unit (SDU), the world's first birth facility exclusively for mothers carrying babies with known birth defects, Children's Hospital of Philadelphia (CHOP) is celebrating its 5,000th delivery.
  • "Traditionally, these mothers will give birth in one hospital, and their newborn will be transferred to a specialized pediatric hospital shortly after delivery.
  • "The Garbose Special Delivery Unit is a very important part of the comprehensive care our Center for Fetal Diagnosis and Treatment is able to provide."
  • About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

Children's Hospital of Philadelphia Celebrates 26th Annual Fetal Surgery Family Reunion at the Philadelphia Zoo

Retrieved on: 
Monday, June 6, 2022
Children's Hospital of Philadelphia, Non-functional testing, Research, Congenital diaphragmatic hernia, Morbilliform, Philadelphia Zoo, Center, Hope, Birth defect, Health, Patient, Surgeon, Medical director, Spina bifida, Human, Prussia, Mother, Hospital, Birth, CFDT, Philadelphia, CHOP, Birth control, Medicine, Treatment

PHILADELPHIA, June 5, 2022 /PRNewswire/ -- Today, more than 3,000 people gathered at the Philadelphia Zoo to celebrate the 26th Children's Hospital of Philadelphia (CHOP) Fetal Family Reunion, with patients and families from more than 20 states attending the first in-person reunion in two years. The event, hosted by CHOP's Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment (CFDT), provided an opportunity for those treated in the center to reconnect with their care team and other families who share an indescribable bond.

Key Points: 
  • Babies diagnosed with these birth defects before birth either underwent fetal surgery to treat the condition before birth or received highly complex care immediately after birth.
  • "The Fetal Family Reunion has always been my favorite day of the year, but it carries even more significance today to gather in-person together once again."
  • CHOP's Fetal Family Reunion has been an annual occurrence since 1997 and has grown from a handful of attendees the first year to more than 650 families today.
  • About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

Worldwide Cardiovascular and Soft Tissue Repair Patches Industry to 2030 - Featuring Baxter, LabCor and Neovasc Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 1, 2022
Medical Supplies, Medical Devices, Health, Surgery, Cardiology, Biotechnology, Umbilical hernia, Adoption, Ventricular septal defect, Degenerative disease, Death, Congenital diaphragmatic hernia, Ascites, Prevalence, Korea Disease Control and Prevention Agency, Coronary heart disease, susceptibility to, 8, Risk, Birth defect, Growth, Smoking, ASD, Chronic cough, Hernia, Obesity, Inguinal hernia, Atrial septal defect, Constipation, Center, Pressure, World Health Organization, Incidence, Polytetrafluoroethylene, Pharmaceutical industry, Health insurance

In addition, increasing implementation of patches in medical procedures and growing sports injuries is expected to support the development and growth of the market over the forthcoming years.

Key Points: 
  • In addition, increasing implementation of patches in medical procedures and growing sports injuries is expected to support the development and growth of the market over the forthcoming years.
  • One of the key driving market forces is the rapidly rising prevalence of cardiovascular diseases.
  • As per World Health Organization estimates, cardiovascular diseases account for the largest share of 32% or 17.9 million deaths annually.
  • As per the Centers for Disease Control and Prevention estimates, approximately 695,000 deaths in the U.S. are due to underlying cardiac diseases.

Renowned Pediatric Surgeon Appointed Director of Children's Surgical Services at Hassenfeld Children's Hospital at NYU Langone

Retrieved on: 
Thursday, January 13, 2022
Hernia, NYU Langone Health, General surgery, NYU, Hassenfeld Children's Hospital, Boston University School of Medicine, Patient, Pediatric surgery, Abdomen, Congenital diaphragmatic hernia, New York University Grossman School of Medicine, Surgeon, NewYork-Presbyterian Hospital, Division, Retirement, Bachelor of Arts, Human, Low-threshold treatment programs, Program, Non-functional testing, Boston University, American Academy, Pediatrics (journal), 2021 Essex County Council election, Columbia, Appendicitis, Department, Cincinnati Children's Hospital Medical Center, Leadership, American Pediatric Surgical Association, Faculty, Education, Hospital, Fellowship of the Royal Colleges of Surgeons, Howard, PAT, American College, Empathy, Friends, Dentistry, Medicine, Pediatrics, Pediatrics, MD

NEW YORK, Jan. 13, 2022 /PRNewswire/ -- Nationally renowned pediatric surgeon Jason C. Fisher, MD, has been named director of the Division of Pediatric Surgery , the William F. and Virginia Connolly Mitty Associate Professor of Pediatric Surgery at NYU Grossman School of Medicine, and director of Children's Surgical Services at Hassenfeld Children's Hospital at NYU Langone .

Key Points: 
  • NEW YORK, Jan. 13, 2022 /PRNewswire/ -- Nationally renowned pediatric surgeon Jason C. Fisher, MD, has been named director of the Division of Pediatric Surgery , the William F. and Virginia Connolly Mitty Associate Professor of Pediatric Surgery at NYU Grossman School of Medicine, and director of Children's Surgical Services at Hassenfeld Children's Hospital at NYU Langone .
  • In addition to his new positions, he will continue to serve as the surgical director of NYU Langone's Pediatric ECMO Program .
  • He will also continue to co-direct the Fetal Diagnosis and Treatment Program , in which pediatric, neonatal, and surgical subspecialists collaborate with maternalfetal medicine specialists to manage prenatal conditions.
  • An accomplished surgeon and leader, Fisher uses laparoscopic and minimally invasive surgical techniques, to address a wide range of surgical conditions in the chest and abdomen.

Global Membrane Oxygenators (Hollow Fiber, Flat Sheet) Market Analysis Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 18, 2021
Medical Devices, Health, Industry, Respiratory failure, Jean-Louis Vincent, CAGR, Oxygen, Transport, Death, Myocardial infarction, Adoption, Incidence, Congenital diaphragmatic hernia, Prevalence, Cardiac arrest, CVD, Hospital, Pulmonary hypertension, Chronic obstructive pulmonary disease, Cardiovascular disease, ECMO, Carbon, Adult, WHO, Patient, Pneumonia, COVID-19, USD, Medical device

The global membrane oxygenators market size is expected to reach USD 141.5 million by 2028, expanding at a CAGR of 1.5%

Key Points: 
  • The global membrane oxygenators market size is expected to reach USD 141.5 million by 2028, expanding at a CAGR of 1.5%
    Key factors expected to boost the market include the growing prevalence of respiratory failures and cardiopulmonary diseases.
  • Furthermore, there has been a rise in the number of patients suffering from COVID-19 and chronic obstructive pulmonary disease, which can require membrane oxygenators for treatment, enhancing their adoption.
  • Leading market participants operating in this industry are focusing on developing technologically advanced membrane oxygenators.
  • Portable adaptors and compact membrane oxygenators in ECMO circuits have also been developed, which help in the transportation of critically ill patients.

LGCY Power Hosts Charity Event to Support Tiny Hero and Fight Against Congenital Diaphragmatic Hernias

Retrieved on: 
Tuesday, August 7, 2018
Congenital diaphragmatic hernia, CDH, Sunrun, UTAH, Diaphragmatic hernia, Hernia, Lehi, United States

LEHI, Utah, Aug. 7, 2018 /PRNewswire/ --LGCY Power (LGCY) https://www.lgcypower.com/ , a Sunrun Certified Partner, today announced that beginning August 7, 2018 the company will host a special weeklong charity event to raise money in support of the Utah based non-profit organization, Tiny Hero and the fight against Congenital Diaphragmatic Hernias (CDH).

Key Points: 
  • LEHI, Utah, Aug. 7, 2018 /PRNewswire/ --LGCY Power (LGCY) https://www.lgcypower.com/ , a Sunrun Certified Partner, today announced that beginning August 7, 2018 the company will host a special weeklong charity event to raise money in support of the Utah based non-profit organization, Tiny Hero and the fight against Congenital Diaphragmatic Hernias (CDH).
  • During the week, the LGCY sales team can donate a percentage of sales to Tiny Hero.
  • Tiny Hero was established in 2014 by Steve and Annie Zolman to help families affected by CDH find the best care, a supportive community and a hope filled future.
  • A Sunrun Certified Partner, LGCY has grown to offices in 16 states with headquarters inLehi, Utah.